The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors.
3 Primary · 4 Secondary · Reporting Duration: Up to approximately 27 months
90 Total Participants · 2 Treatment Groups
Primary Treatment: MK-6598 + Pembrolizumab · No Placebo Group · Phase 1
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: